Leadless pacemaker study assesses safety and efficacy (LEADLESS II trial)

Antiarrythmia drugs no impact on late AF recurrence (EAST-AF trial)

Determining Optimal non­invasive Parameters for the Prediction of Left vEntricular morphologic and functional Remodeling in Chronic Ischemic Patients: the emerging role of left ventricular end diastolic volume (LVEDV)

ELIXA trial shows CV safety of lixisenatide

SCOT study quells concern about NSAID safety

OPTIDUAL trial results suggest extending post­stenting DAPT beyond one year

Trial Evaluating Cardiovascular Outcomes with Sitagliptin in patients with type-2 Diabetes: TECOS

New mineralocorticoid receptor agonist for heart failure

Spironolactone “A Clear Winner” for Resistant Hypertension

Half­Dose Combo of Common Diuretics a “Win­Win” for Hypertension: PATHWAY­3

CVD biomarkers respond better to telmisartan than non­ARB blood pressure medications

New combination LCZ696 provides significant improvement in arterial stiffness

Automated pulmonary congestion alert no benefit in heart failure trial

BENEFIT study: antiparasitics for Chagas cardiomiopathy

Largest study to date shows no benefit to gene transfer therapy in heart failure

Non­invasive blood flow measurements reduce invasive tests in chest pain patients (PLATFORM trial)

High sensitivity troponin trial

Fix dose combination in hypertensive patients

Management of bleeding and emergency procedures in anticoagulated patients

Highlights in sports cardiology

Benefits of fixed dose combinations in hypertension

A major clinical issue ­ Correcting iron deficiency in heart failure patients

New data of TECOS trial regarding heart failre patient population

Very exciting results of the PATHWAY 2 trial on resistant hypertension and the PARAMETER trial on new combination improving arterial stiffness

Reception of ELIXA trials results in scientific community

The ATTEMPT­CVD ­ trial of telmisartan prevention of cardiovascular disease

On the congress

OPTIDUAL trial

Energizing the Heart - Trimetadizin

Patient centered approach - multiple risk factors

Targeting plasma PCSK9 as a promising approach to improve outcomes

PCSK9 inhibitors